Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hycor

This article was originally published in The Gray Sheet

Executive Summary

Plans to close its Portland, Maine Ventrex allergy diagnostic and immunodiagnostic product manufacturing facility by late July. The firm will consolidate the operations from the 70,000-square- foot facility into its Garden Grove, California facility. Hycor will record a one-time after-tax charge of approximately $800,000, which will include "all costs associated with the Portland facility closure, severance and outplacement programs, and the integration of Ventrex operations into the Garden Grove facility." The firm, which anticipates an eighteen-month payback on the expenses, expects that the closure and consolidation will yield annual after-tax savings of approximately $500,000.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel